靶向治疗对早期非小细胞肺癌的生存质量的队列研究

摘要

Objective:To observe the targeting therapy of early stage non small cell lung cancer (NSCLC) affect the life quality and immune function of patients.Method:126 patients with early non small cell lung cancer in our hospital from June 2014 to May 2016 were selected as the objects of study,they were randomly divided into molecular targe group of 76 cases and conventional treatment group of 50 cases.The molecular targe group was given drug therapy for the treatment,the dose for Gefitinib Imatinib 250 mg/d,Erlotinib Erlotinib 150 mg/d, ALK positive detection by Eck for Nigerian 125 mg/time,3 times a day,continuous treatment for 12 months. The conventional treatment group was given adjuvant chemotherapy. of therapeutic effect, quality of life, immune function and adverse reactions of two groups were observed.Result:The total effective rate and disease control rate of two groups had no significant difference(P>0.05); there were statistically significant differences of KPS score in molecular target group before and after treatment(P<0.05),after treatment,the KPS score of two groups had statistically significant difference(P<0.05);the quality life of two groups after treatment had statistically significant difference(P<0.05),and molecular targeted group of that was better than control group, the difference was statistically significant(P<0.05).The main adverse reactions were rash, diarrhea, nausea and ulcers,but it had no effect on anti tumor therapy.Conclusion:The targeted therapy for early stage non-small cell lung cancer patients can improve the life quality and immune function of patients.%目的：观察靶向治疗对早期非小细胞肺癌（NSCLC）患者生活质量的影响。方法：选择2014年6月-2016年5月期间在本院接受治疗的126例早期非小细胞肺癌患者为研究对象，将患者随机分为分子靶向组76例与传统治疗组50例。分子靶向组术后给予吉非替尼等靶向药物治疗，剂量为吉非替尼250 mg/d，厄洛替尼150 mg/d，ALK检测阳性者采用埃克替尼125 mg/次，3次/d治疗，持续服药12个月，传统治疗组进行辅助化疗。观察两组患者治疗效果、生活质量及不良反应。结果：两组患者总有效率、疾病控制率比较差异均无统计学意义（P>0.05）；分子靶向组治疗后KPS评分与治疗前及对照组比较差异均有统计学意义（P<0.05）；两组患者治疗后生活质量评分与治疗前比较差异均有统计学意义（P<0.05）；分子靶向组患者治疗后生活明显质量改善，与对照组比较差异有统计学意义（P<0.05）。主要不良反应为皮疹、腹泻、恶心和溃疡等，但未影响抗肿瘤治疗。结论：早期非小细胞肺癌患者的靶向治疗方案能够提高患者生活质量。